0001677077 2025-05-01 2026-04-30 0001677077 2025-10-31 0001677077 2026-07-22 0001677077 2026-02-01 2026-04-30 0001677077 alzn:StephanJackmanMember 2026-04-30 0001677077 alzn:StephanJackman1Member 2026-04-30 0001677077 alzn:DavidJ.KatzoffMember 2026-04-30 0001677077 alzn:DavidJ.Katzoff1Member 2026-04-30 0001677077 alzn:DavidJ.Katzoff2Member 2026-04-30 0001677077 alzn:DavidJ.Katzoff3Member 2026-04-30 0001677077 alzn:DavidJ.Katzoff4Member 2026-04-30 0001677077 2026-04-30 0001677077 2025-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2026-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2025-04-30 0001677077 us-gaap:SeriesCPreferredStockMember 2026-04-30 0001677077 us-gaap:SeriesCPreferredStockMember 2025-04-30 0001677077 2024-05-01 2025-04-30 0001677077 alzn:SeriesAConvertiblePreferredStockMember 2024-04-30 0001677077 alzn:SeriesBConvertiblePreferredStockMember 2024-04-30 0001677077 alzn:SeriesCConvertiblePreferredStockMember 2024-04-30 0001677077 us-gaap:CommonStockMember 2024-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001677077 us-gaap:RetainedEarningsMember 2024-04-30 0001677077 2024-04-30 0001677077 alzn:SeriesAConvertiblePreferredStockMember 2025-04-30 0001677077 alzn:SeriesBConvertiblePreferredStockMember 2025-04-30 0001677077 alzn:SeriesCConvertiblePreferredStockMember 2025-04-30 0001677077 us-gaap:CommonStockMember 2025-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001677077 us-gaap:RetainedEarningsMember 2025-04-30 0001677077 alzn:SeriesAConvertiblePreferredStockMember 2024-05-01 2025-04-30 0001677077 alzn:SeriesBConvertiblePreferredStockMember 2024-05-01 2025-04-30 0001677077 alzn:SeriesCConvertiblePreferredStockMember 2024-05-01 2025-04-30 0001677077 us-gaap:CommonStockMember 2024-05-01 2025-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2024-05-01 2025-04-30 0001677077 us-gaap:RetainedEarningsMember 2024-05-01 2025-04-30 0001677077 alzn:SeriesAConvertiblePreferredStockMember 2025-05-01 2026-04-30 0001677077 alzn:SeriesBConvertiblePreferredStockMember 2025-05-01 2026-04-30 0001677077 alzn:SeriesCConvertiblePreferredStockMember 2025-05-01 2026-04-30 0001677077 us-gaap:CommonStockMember 2025-05-01 2026-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2025-05-01 2026-04-30 0001677077 us-gaap:RetainedEarningsMember 2025-05-01 2026-04-30 0001677077 alzn:SeriesAConvertiblePreferredStockMember 2026-04-30 0001677077 alzn:SeriesBConvertiblePreferredStockMember 2026-04-30 0001677077 alzn:SeriesCConvertiblePreferredStockMember 2026-04-30 0001677077 us-gaap:CommonStockMember 2026-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001677077 us-gaap:RetainedEarningsMember 2026-04-30 0001677077 alzn:AtTheMarketMember 2025-05-01 2026-04-30 0001677077 2026-01-31 0001677077 us-gaap:StockOptionMember 2025-05-01 2026-04-30 0001677077 us-gaap:StockOptionMember 2024-05-01 2025-04-30 0001677077 us-gaap:WarrantMember 2025-05-01 2026-04-30 0001677077 us-gaap:WarrantMember 2024-05-01 2025-04-30 0001677077 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2024-06-14 0001677077 2023-05-01 2024-04-30 0001677077 alzn:FederalMember 2025-05-01 2026-04-30 0001677077 us-gaap:CaliforniaFranchiseTaxBoardMember 2025-05-01 2026-04-30 0001677077 alzn:NorthCarolinaMember 2025-05-01 2026-04-30 0001677077 alzn:OtherMember 2025-05-01 2026-04-30 0001677077 us-gaap:StateAndLocalJurisdictionMember 2026-04-30 0001677077 us-gaap:DomesticCountryMember 2026-04-30 0001677077 alzn:StockIncentivePlan2016Member 2016-04-30 0001677077 alzn:StockIncentivePlan2016Member 2019-02-28 2019-03-01 0001677077 alzn:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 alzn:StockIncentivePlan2021Member 2021-02-28 0001677077 alzn:StockIncentivePlan2021Member 2021-02-01 2021-02-28 0001677077 alzn:EmployeesAndDirectorsMember 2024-05-01 2025-04-30 0001677077 alzn:PerformanceContingentStockOptionsMember alzn:KeyEmployeesAndDirectorMember 2019-11-25 2019-11-26 0001677077 alzn:UnamortizedStockBasedCompensationMember 2026-04-30 0001677077 alzn:StockBasedCompensationMember 2025-05-01 2026-04-30 0001677077 alzn:ResearchAndDevelopmentExpensesMember 2025-05-01 2026-04-30 0001677077 alzn:ResearchAndDevelopmentExpensesMember 2024-05-01 2025-04-30 0001677077 alzn:GeneralAndAdministrativeExpensesMember 2025-05-01 2026-04-30 0001677077 alzn:GeneralAndAdministrativeExpensesMember 2024-05-01 2025-04-30 0001677077 alzn:Warrant2026Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant2025Member 2024-05-01 2025-04-30 0001677077 alzn:Warrant2025Member 2025-04-30 0001677077 alzn:Warrant1Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant1Member 2026-04-30 0001677077 alzn:Warrant2Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant2Member 2026-04-30 0001677077 alzn:Warrant3Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant3Member 2026-04-30 0001677077 alzn:Warrant4Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant4Member 2026-04-30 0001677077 alzn:Warrant5Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant5Member 2026-04-30 0001677077 alzn:Warrant6Member 2025-05-01 2026-04-30 0001677077 alzn:Warrant6Member 2026-04-30 0001677077 alzn:ExercisePrice1Member 2026-04-30 0001677077 alzn:ExercisePrice2Member 2026-04-30 0001677077 alzn:ExercisePrice3Member 2026-04-30 0001677077 alzn:ExercisePrice4Member 2026-04-30 0001677077 srt:MinimumMember 2026-04-30 0001677077 srt:MaximumMember 2026-04-30 0001677077 us-gaap:WarrantMember 2025-04-30 0001677077 us-gaap:WarrantMember 2025-05-01 2026-04-30 0001677077 us-gaap:WarrantMember 2026-04-30 0001677077 us-gaap:WarrantMember 2024-05-01 2025-04-30 0001677077 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2025-04-30 0001677077 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2025-04-30 0001677077 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2025-04-30 0001677077 alzn:AL001LicenseMember 2018-07-01 2018-07-02 0001677077 alzn:AL001LicenseMember alzn:FirstAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzn:AL001LicenseMember alzn:SecondAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzn:AL001LicenseMember alzn:ThirdAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzn:ALZN002LicenseMember 2016-04-29 2016-05-02 0001677077 alzn:ALZN002LicenseMember alzn:FirstAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzn:ALZN002LicenseMember alzn:SecondAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzn:ALZN002LicenseMember alzn:ThirdAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzn:AdditionalAL001LicenseMember 2019-11-01 2019-11-19 0001677077 alzn:AdditionalAL001LicenseMember alzn:FirstAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzn:AdditionalAL001LicenseMember alzn:SecondAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzn:AdditionalAL001LicenseMember alzn:ThirdAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzn:PreIndMeetingMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:PreIndMeetingMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:IndApplicationFilingMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:IndApplicationFilingMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFirstDosingOfPatientInClinicalTrialMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:UponFirstDosingOfPatientInClinicalTrialMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponCompletionOfFirstClinicalTrialMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:UponCompletionOfFirstClinicalTrialMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFdaNdaApprovalMember alzn:AL001LicenseMember 2026-04-30 0001677077 alzn:UponFdaNdaApprovalMember alzn:AL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponINDApplicationFilingMember alzn:ALZN002LicenseMember 2026-04-30 0001677077 alzn:UponINDApplicationFilingMember alzn:ALZN002LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzn:ALZN002LicenseMember 2026-04-30 0001677077 alzn:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzn:ALZN002LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponCompletionOfFirstPhaseIIClinicalTrialMember alzn:ALZN002LicenseMember 2026-04-30 0001677077 alzn:UponCompletionOfFirstPhaseIIClinicalTrialMember alzn:ALZN002LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzn:ALZN002LicenseMember 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzn:ALZN002LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFDABLAApprovalMember alzn:ALZN002LicenseMember 2026-04-30 0001677077 alzn:UponFDABLAApprovalMember alzn:ALZN002LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzn:AdditionalAL001LicenseMember 2026-04-30 0001677077 alzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzn:AdditionalAL001LicenseMember 2025-05-01 2026-04-30 0001677077 alzn:FirstCommercialSaleMember alzn:AdditionalAL001LicenseMember 2026-04-30 0001677077 alzn:FirstCommercialSaleMember alzn:AdditionalAL001LicenseMember 2025-05-01 2026-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2024-01-31 0001677077 alzn:SeriesBConvertiblePreferredStockMember alzn:SecuritiesPurchaseAgreementsMember alzn:AultLendingMember 2024-01-01 2024-01-31 0001677077 us-gaap:SeriesBPreferredStockMember 2023-05-01 2024-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2024-04-30 0001677077 us-gaap:SeriesBPreferredStockMember 2025-05-01 2026-04-30 0001677077 us-gaap:SeriesCPreferredStockMember alzn:SecuritiesPurchaseAgreementsMember alzn:OrchidFinanceMember 2025-02-01 2025-02-28 0001677077 us-gaap:SeriesCPreferredStockMember 2025-02-28 0001677077 us-gaap:SeriesCPreferredStockMember 2025-04-01 2025-04-28 0001677077 us-gaap:SeriesCPreferredStockMember 2025-05-01 2025-05-29 0001677077 us-gaap:SeriesCPreferredStockMember 2025-06-02 2025-06-03 0001677077 us-gaap:SeriesCPreferredStockMember 2025-06-10 2025-06-12 0001677077 us-gaap:SeriesCPreferredStockMember 2025-06-11 2025-06-13 0001677077 us-gaap:SeriesCPreferredStockMember 2024-05-01 2025-04-30 0001677077 us-gaap:SeriesCPreferredStockMember 2025-05-01 2026-04-30 0001677077 alzn:October2024ATMMember 2024-05-01 2025-04-30 0001677077 alzn:March2026ATMMember 2025-05-01 2026-04-30 0001677077 us-gaap:SubsequentEventMember 2026-05-01 2026-07-22 iso4217:USD shares iso4217:USD shares pure false 2026 FY 0001677077

10-K true 2026-04-30 --04-30 false 001-40483 ALZAMEND NEURO, INC. DE 81-1822909 3480 Peachtree Road NE Second Floor Suite 103 Atlanta GA 30326 844 722-6333 Common Stock, $0.0001 par value per share ALZN NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 9600000 4791525 None Information Security Program The mission of our information security program is to design, implement, and maintain a comprehensive information security program that protects our systems, services, and data against unauthorized access, disclosure, modification, damage, and loss. Our information security program is comprised of internal and external security and technology professionals who work collaboratively to identify, assess, manage, and mitigate cybersecurity risks and threats across the Company and third-party contractors. <p class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_981_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250501__20260430_zdr0T9sktRBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250501__20260430_z9QayYcByYzd">We recognize the importance of effectively managing material risks associated with cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk management program integrates the monitoring and management of these risks and threats and is informed by applicable laws, regulations, industry standards, and best practices. We continue to invest in information security resources to mature, expand, and adapt our capabilities to address emerging cybersecurity risks and threats. Our information security organization is committed to maintaining a robust and resilient security posture that enables us to protect our assets, maintain our stakeholders' trust, and support our business's overall success. Cybersecurity Risk Management and Strategy <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250501__20260430_zQMyC6j2kmpa">Our cybersecurity risk management and strategy are integral components of our comprehensive information security program. They guide our continuous efforts to evaluate and improve the confidentiality, integrity, and availability of our critical systems, data, and operations. We have adopted an Information Security Policy (the “Info-Sec Policy”) and an Incident Response Plan (the “Response Plan”) that establish administrative, physical, and technical controls and procedures to protect sensitive data throughout the Company. These policies also outline processes to assess, identify, manage, and report cybersecurity risks and incidents. The Info-Sec Policy applies to all persons working for the Company and any third parties working with us in any capacity. Our approach to controls and risk management is informed by applicable laws and regulations, as well as industry standards and best practices. These serve as a guide to help us identify, assess, and manage cybersecurity controls and risks relevant to our business. Our cybersecurity risk management program includes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">1.</td><td style="text-align: justify">Identifying cybersecurity risks that could impact our facilities, third-party vendors/partners, operations, critical systems, information, and broader enterprise information technology environment. Risks are informed by threat intelligence, current and historical adversarial activity, and industry-specific threats;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">2.</td><td style="text-align: justify">Performing cybersecurity risk assessments to evaluate our readiness if the risks were to materialize;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">3.</td><td style="text-align: justify">Ensuring risk is addressed and tracking any necessary remediation through an action plan;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">4.</td><td style="text-align: justify">Analyzing all third-party vendors for compliance with our internal Info-Sec Policy to assess potential risks associated with their security controls. We generally require third parties to maintain security controls, notify us promptly of any data breach or cybersecurity incident that may impact our data, and provide written assurance of corrective actions; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">5.</td><td style="text-align: justify">Engaging and utilizing a comprehensive suite of security solutions, including enterprise mobility management, endpoint protection, secure file transfer, and security information and event management to monitor and actively respond to cybersecurity threats. These solutions work together to secure our endpoints, protect against malware, ensure the safe transfer of files, and provide our cybersecurity team with the functionality to build alerts on specific use cases that are important and unique to our business.</td> </tr></table> true We recognize the importance of effectively managing material risks associated with cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk management program integrates the monitoring and management of these risks and threats and is informed by applicable laws, regulations, industry standards, and best practices. We continue to invest in information security resources to mature, expand, and adapt our capabilities to address emerging cybersecurity risks and threats. true Cybersecurity Governance <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250501__20260430_zMSGO98YCqqk">Our Board oversees cybersecurity risk as part of its overall risk oversight function. We utilize resources from Hyperscale Data, Inc. (“HDI”) to act as our information technology department (the “IT Department”), which functions as our Information Security Advisory Team. The IT Department is responsible for managing our information security program and implementing cybersecurity risk management practices. The IT Department collaborates with various stakeholders across the organization to identify, assess, and mitigate cybersecurity risks. They regularly monitor and adapt our information security program to address the evolving threat landscape. In the event of a cybersecurity incident, the IT Department promptly reports the matter to our Chief Financial Officer. The Chief Financial Officer is responsible for assessing the severity and potential impact of the incident and determining the appropriate course of action. The Chief Financial Officer keeps the Board informed of significant cybersecurity incidents and provides updates on the overall status of our cybersecurity program as needed. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250501__20260430_zjngATtJzYp2">This governance structure ensures that cybersecurity risks are effectively managed by the IT Department, with oversight from the Chief Financial Officer and the Board. It maintains clear lines of communication and accountability, enabling timely decision-making and response to cybersecurity matters. During fiscal 2026, we did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial condition. However, despite our efforts, we may not successfully eliminate all risks from cybersecurity threats and can provide no assurance that undetected cybersecurity incidents have not occurred. Our Board oversees cybersecurity risk as part of its overall risk oversight function. We utilize resources from Hyperscale Data, Inc. (“HDI”) to act as our information technology department (the “IT Department”), which functions as our Information Security Advisory Team. The IT Department is responsible for managing our information security program and implementing cybersecurity risk management practices. This governance structure ensures that cybersecurity risks are effectively managed by the IT Department, with oversight from the Chief Financial Officer and the Board. It maintains clear lines of communication and accountability, enabling timely decision-making and response to cybersecurity matters. false false false false true The timing of any equity grants to executive officers in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive officer’s commencement of employment or promotion effective date). As a result, in all cases, the timing of grants of equity awards, including stock options, occurs independent of the release of any material nonpublic information, and we do not time the disclosure of material nonpublic information for the purpose of affecting the value of equity-based compensation. false The following table provides information on outstanding equity awards as of April 30, 2026 awarded to our named executive officers: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="16" style="white-space: nowrap; font-weight: bold; text-align: center">OUTSTANDING EQUITY AWARDS AT APRIL 30, 2026</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Name</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options (#) Exercisable</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options (#) Unexercisable</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Option Awards Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Option Exercise Price ($)</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Option Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 27%; text-align: left">Stephan Jackman</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">740</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">741</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">741</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1,579.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 12%; text-align: right">11/29/2032</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">11/13/2035</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> David J. Katzoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">296</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,350.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">1/21/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,025.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">11/1/2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,025.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">11/26/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,025.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">11/18/2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">11/13/2035</td> </tr> </table> Stephan Jackman Stephan Jackman 740 1579.50 225000 2.33 David J. Katzoff David J. Katzoff David J. Katzoff David J. Katzoff David J. Katzoff 296 1350.00 630 2025.00 185 2025.00 2025.00 150000 2.33 200 HASKELL & WHITE LLP Irvine, California

710689

3948658

1053808

228719

1764497

4177377

314866

425606

2079363

4602983

1346152

634761

1346152

634761

1000

0 6000

2100

10000

0 1000

150.7176

0.0001

300000000

4256039

778733

425

68040429

62503405

-67307643

-58535261

733211

3968222

2079363

4602983

3629785

1414928

5137056

3081896

8766841

4496824

-8766841

-4496824

1078

6619

18029

-5541

-18029

-8772382

-4514853

117022

473209

-8772382

-5105084

-2.63

-11.32

3337143

450799

2100

76444

51426215

-54020408

-2594185

235907 24 2704028 2704052 18 800 75 7736144 7736144 1111

600

-712 -24 465253 46 -46 311356 311356 -97 97 325108 325108

-4514853

2100

150

778733

62503405

-58535261

3968222

451298 45 794799 794844 425 4035000 4035000 -2100 -575 302 -302 707527 707527

-8772382

4256039

425

68040429

-67307643

733211

-8772382

-4514853

110740

50740

9286

707527

325108

825089

149525

711391

-2288942

-8067813

-6568186

300000

-300000

794844

2704052

600

4035000

7736144

4829844

10440796

-3237969

3572610

3948658

376048

710689

3948658

7120133 2100000 5757176 239712 1635489

117022

311356 977511 577073

1. DESCRIPTION OF BUSINESS Organization Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With two current product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor. The Company is devoting substantially all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”) and its preferred stock, par value $0.0001 per share. The Company expects to continue to incur net losses in the foreseeable future. Reverse Stock Split On July 10, 2024, pursuant to the authorization provided by the Company’s stockholders at its annual meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of one-for-ten (the “Second Reverse Split”). The Second Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second Reverse Split, each ten shares of Common Stock issued and outstanding prior to the Second Reverse Split were converted into one share of Common Stock. The Second Reverse Split became effective in the State of Delaware on July 16, 2024. All share amounts in these financial statements have been updated for all periods presented to reflect the Second Reverse Split. On May 6, 2025, pursuant to the authorization provided by the Company’s stockholders at its annual meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of one-for-nine (the “Reverse Split”). The Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Reverse Split, each nine shares of Common Stock issued and outstanding prior to the Reverse Split were converted into one share of Common Stock. The Reverse Split became effective in the State of Delaware on May 12, 2025. All share amounts in these financial statements have been updated for all periods presented to reflect the Reverse Split.

0.0001

2. LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. As of April 30, 2026, the Company had cash of $711,000 and an accumulated deficit of $67.3 million. For the year ended April 30, 2026, the Company had a net loss of $8.8 million and cash used in operating activities of $8.1 million. The Company had cash as of April 30, 2025, totaling $3.9 million and accumulated deficit of $58.5 million. In the past, the Company has financed its operations principally through issuances of equity and debt instruments. During the year ended April 30, 2026, the Company sold an aggregate of 451,298 shares of Common Stock pursuant to an at-the-market offering for proceeds of $795,000 (see Note 9). The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report. These factors create substantial doubt about our ability to continue as a going concern. In order to continue as a going concern, the Company will need to raise additional funds. The Company plans to seek additional funding through public equity, private equity and debt financings. The terms of any additional financing may adversely affect the holdings or rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs and planned clinical trials which could adversely affect the Company’s business operations. On March 20, 2026, the Company was notified by the staff of The Nasdaq Stock Market LLC (“Nasdaq”) that that its stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of January 31, 2026 was approximately $2.2 million. As reported in this Annual Report, the Company’s stockholders’ equity as of April 30, 2026 was approximately $0.7 733,211 million. In accordance with Nasdaq Listing Rules, the Company was provided an initial period of 45 calendar days, or until May 4, 2026, to submit a plan to regain compliance. On May 4, 2026, the Company submitted a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1) to Nasdaq. On May 19, 2026, Nasdaq granted the Company an extension of time to regain compliance on or before September 16, 2026.

711000

67300000

8800000

8100000

3900000

58500000

451298

795000

2200000

733211

3. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2026 and 2025, the Company had no cash equivalents. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase common stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying common stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the warrants’ contractual life. Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2026, the Company had fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2026, there were no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements. Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for restricted stock is based upon the estimated fair value of the Common Stock on the date of grant. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally requires significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different. Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”), depending on the specific terms of the warrant agreement. During the year ended April 30, 2026, based on the terms of the Company’s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815. Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the additional common shares had been issued and if such common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options, restricted stock units and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Since the effects of outstanding options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zuW6zJ02Qrdg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended April 30,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,972</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Preferred Stock Classification The Company analyzes the terms of its preferred stock using ASC Topic No. 480, Distinguishing Liabilities from Equity, to determine whether the Company’s preferred stock should be classified as a liability or equity, and if classified as equity, permanent or temporary. Common criteria the Company considers are redemption provisions, conversion options, mandatory fixed dividends, discretionary dividends based on earning, voting rights and collateral requirements. Segment Reporting In fiscal year 2025, the Company adopted Accounting Standard Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The Company operates as a single operating and reportable segment, which reflects the manner in which the Chief Operating Decision Maker, who is the Company’s Chief Executive Officer, manages the business and allocates resources. The Company is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD, with key operational decisions based on cash availability, development milestones, and return on investment associated with future manufacturing and commercialization opportunities. Recent Accounting Standards On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires entities to disclose specific rate reconciliations, amount of income taxes separated by federal and individual jurisdiction, and the amount of income (loss) from continuing operations before income tax expense (benefit) disaggregated between federal, state, and foreign. The Company adopted this for its fiscal year beginning May 1, 2025, prospectively. Adoption impacted footnote disclosures only, with no material effect on financial position or results of operations. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, to require disaggregated disclosure of certain income statement expense line items, such as purchases of inventory, employee compensation, and depreciation and amortization. The new standard is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied prospectively, but retrospective application is permitted. Management is currently evaluating the impact of this guidance on its financial statements.

Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”).

Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.

Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of April 30, 2026 and 2025, the Company had no cash equivalents.

Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase common stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying common stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the warrants’ contractual life.

Income Taxes The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized. As of April 30, 2026, the Company had fully reserved the net deferred income tax assets by taking a full valuation allowance against these assets. The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2026, there were no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements.

Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for restricted stock is based upon the estimated fair value of the Common Stock on the date of grant. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally requires significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.

Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”), depending on the specific terms of the warrant agreement. During the year ended April 30, 2026, based on the terms of the Company’s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815.

Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the additional common shares had been issued and if such common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options, restricted stock units and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Since the effects of outstanding options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zuW6zJ02Qrdg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended April 30,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,972</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zuW6zJ02Qrdg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended April 30,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,972</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250430_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1597000

12854

135972

137051

1732972

149905

Preferred Stock Classification The Company analyzes the terms of its preferred stock using ASC Topic No. 480, Distinguishing Liabilities from Equity, to determine whether the Company’s preferred stock should be classified as a liability or equity, and if classified as equity, permanent or temporary. Common criteria the Company considers are redemption provisions, conversion options, mandatory fixed dividends, discretionary dividends based on earning, voting rights and collateral requirements.

Segment Reporting In fiscal year 2025, the Company adopted Accounting Standard Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The Company operates as a single operating and reportable segment, which reflects the manner in which the Chief Operating Decision Maker, who is the Company’s Chief Executive Officer, manages the business and allocates resources. The Company is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD, with key operational decisions based on cash availability, development milestones, and return on investment associated with future manufacturing and commercialization opportunities.

Recent Accounting Standards On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires entities to disclose specific rate reconciliations, amount of income taxes separated by federal and individual jurisdiction, and the amount of income (loss) from continuing operations before income tax expense (benefit) disaggregated between federal, state, and foreign. The Company adopted this for its fiscal year beginning May 1, 2025, prospectively. Adoption impacted footnote disclosures only, with no material effect on financial position or results of operations. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, to require disaggregated disclosure of certain income statement expense line items, such as purchases of inventory, employee compensation, and depreciation and amortization. The new standard is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied prospectively, but retrospective application is permitted. Management is currently evaluating the impact of this guidance on its financial statements.

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets were as follows: <table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zayN0Vi8VNdd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20260430_z1ztoGk6SpKd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250430_z66aQv8yWCZ1" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--PrepaidClinicalTrialFees_iI_pp0d_maPEAOAzslu_zYiBkGBlPn32" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">991,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">178,922</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pp0d_maPEAOAzslu_zSsRVZUlUHZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,584</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzslu_zOx3uvh34zf2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,986</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,213</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0d_mtPEAOAzslu_zRyIfrGjGN68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">228,719</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On June 14, 2025, the Company purchased directors’ and officers’ insurance for 12 months in the amount of $220,000. Prepaid insurance at April 30, 2026 represented the unamortized portion of directors’ and officers’ insurance. In July 2025, the Company initiated its Phase II clinical trial of AL001 in patients with BD. Prepaid clinical trial expenses at April 30, 2026 represented the prepaid expenses association with that trial.

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zayN0Vi8VNdd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20260430_z1ztoGk6SpKd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250430_z66aQv8yWCZ1" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--PrepaidClinicalTrialFees_iI_pp0d_maPEAOAzslu_zYiBkGBlPn32" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">991,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">178,922</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pp0d_maPEAOAzslu_zSsRVZUlUHZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,972</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,584</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzslu_zOx3uvh34zf2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,986</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,213</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0d_mtPEAOAzslu_zRyIfrGjGN68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">228,719</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 991850 178922

41972

42584

19986

7213

1053808

228719

220000

5. INCOME TAXES The following is a geographical breakdown of the Company’s loss before the provision for income taxes: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zO3nEof4Bab2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="display: none; text-align: left">Schedule of loss before provision for income taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20250501__20260430_zAuEFdzTE2kb" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20240501__20250430_zROWpGJ4Gjha" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_iB_zWvUUtRceJM3" style="vertical-align: bottom"> <td style="text-align: left">Pre-tax loss:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_pp0d_maILFCOzAVf_zs7KgB5MYBc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-indent: 11pt">Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(8,771,281</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(4,514,853</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 11pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_pp0d_mtILFCOzAVf_z89INXV8yQq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total pre-tax loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,771,281</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,514,853</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Significant components of the Company’s deferred tax assets were as follows: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9ZnO4zW2AO2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left; text-indent: 11pt">Schedule of deferred tax assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20260430_zNN27OAFWu32" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20250430_z6FMfcwfsXMe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zrmmD6s1IL5f" style="vertical-align: bottom"> <td style="text-align: left">Deferred income tax asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0d_maDTAGzYlE_zwQC5ouMO9Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-indent: 11pt">Accruals</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">3,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures_i01I_pp0d_maDTAGzYlE_zVr86UbjqpL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 11pt">Capitalized research expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,022,954</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzYlE_znCIrcOVlwHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 11pt">Net operating loss carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,950,374</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,566,664</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pp0d_maDTAGzYlE_zA1UeB5EhO0g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,082,661</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,677,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzYlE_zjMkrfxW4qj3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 11pt">Total deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,409,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,271,245</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_pp0d_di_zEhgDFuAlqnh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 11pt">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,114</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,848</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_zra0uNgTyWM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,395,854</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,247,397</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01I_pp0p" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 22pt">Deferred income tax asset, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A reconciliation of the provision for income taxes to the amount computed by applying the 21% statutory U.S. federal income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows: <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zXSZpHQn5Vjl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 98%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_zm59GRfwgoH8" style="display: none; text-align: left">Schedule of effective income tax rate reconciliation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. Federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">(1,841,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and local income tax, net of federal income tax effect (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20250501__20260430_fKDEp_zAZieO1HOKl2" title="State and local income tax, net of federal income tax effect, percent">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Nontaxable / Nondeductible Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-align: left; padding-bottom: 1pt">Stock Compensation – cancellations/expirations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,623,532</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-18.5</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F03_zB3NfADBBsT6" style="width: 0.25in">(1)</td><td id="xdx_F10_zIVyVTHkvKZ2" style="text-align: justify">The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include California.</td></tr></table> A reconciliation of the provision for income taxes to the amount computed by applying the 21% statutory U.S. federal income tax rate to income before income taxes for years prior to the adoption of ASU 2023-09 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Tax benefit at U.S. Federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-32.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increase (decrease) in tax rate resulting from:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-49.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--StockCompensationRate_iP3us-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240501__20250430_z7MNscZ7w8S1" title="Stock-based compensation">-0.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-0.2</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> The amounts of cash income taxes paid by the Company were as follows: <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAmountsAfCashIncomeTaxesPaidTableTextBlock_zwbrN8zHnWpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B7_zSwszEVkE9wc" style="display: none; text-align: left">Schedule of amounts of cash income taxes paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and Local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; width: 82%">California</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-align: left">North Carolina</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Foreign</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes, net of amounts refunded</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In assessing the realization of deferred tax assets, management considers whether it is more likely than not that the Company’s deferred tax assets will be realized. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making such assessments. Given historical generation of and expected future taxable losses, management determined it is more likely than not that some or all of the deferred tax assets will not be realized. Therefore, a full valuation allowance was maintained, as of the years ended April 30, 2026 and 2025, of $15,395,854 and $15,247,397, respectively. At April 30, 2026, the Company maintained U.S. Federal and state net operating loss (“NOL”) carryovers of approximately $55.3 million and $23.8 million, respectively. Federal and state NOLs begin to expire in various years depending on relevant jurisdiction. In accordance with Internal Revenue Code §382 (“IRC §382”), the future deductibility of the Company’s NOL’s may be subject to an annual limitation in the event of a change in control as defined by applicable regulations. The Company has yet to complete a formal study to confirm NOL’s are not limited in utilization per IRC §382 and may reduce applicable deferred tax assets upon completion of such a study, in future periods. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company had no uncertain tax positions as of April 30, 2026. The Company’s policy is to recognize interest and penalties related to income tax matters in the provision for income taxes. As of April 30, 2026, no interest or penalties have been recorded pertaining to uncertain tax positions. The Company is subject to taxation in the United States and various U.S. state jurisdictions. All tax years remain open to examination by the Internal Revenue Service and relevant state authorities. The One Big Beautiful Bill Act (“OBBB Act”) was enacted on July 4, 2025, in the United States. The OBBB Act included several significant provisions, including re-establishing a 100% bonus depreciation deduction, re-establishing rules in calculating business interest expense limitations pursuant to Internal Revenue Code §163(j), changing the calculation of international tax inclusions, and removing the capitalization requirements for domestic research or experimental expenditures paid or incurred in tax years beginning after December 31, 2024. Management has considered applicable tax impacts of the OBBB Act within the financial statements for the fiscal year ended April 30, 2026.

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zO3nEof4Bab2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom"> <td style="display: none; text-align: left">Schedule of loss before provision for income taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20250501__20260430_zAuEFdzTE2kb" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20240501__20250430_zROWpGJ4Gjha" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_iB_zWvUUtRceJM3" style="vertical-align: bottom"> <td style="text-align: left">Pre-tax loss:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_pp0d_maILFCOzAVf_zs7KgB5MYBc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-indent: 11pt">Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(8,771,281</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(4,514,853</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: 11pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_pp0d_mtILFCOzAVf_z89INXV8yQq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total pre-tax loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,771,281</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,514,853</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-8771281

-4514853

-8771281

-4514853

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9ZnO4zW2AO2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left; text-indent: 11pt">Schedule of deferred tax assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20260430_zNN27OAFWu32" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20250430_z6FMfcwfsXMe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zrmmD6s1IL5f" style="vertical-align: bottom"> <td style="text-align: left">Deferred income tax asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0d_maDTAGzYlE_zwQC5ouMO9Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-indent: 11pt">Accruals</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">3,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures_i01I_pp0d_maDTAGzYlE_zVr86UbjqpL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 11pt">Capitalized research expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,022,954</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0d_maDTAGzYlE_znCIrcOVlwHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 11pt">Net operating loss carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,950,374</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,566,664</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pp0d_maDTAGzYlE_zA1UeB5EhO0g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,082,661</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,677,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzYlE_zjMkrfxW4qj3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 11pt">Total deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,409,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,271,245</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_pp0d_di_zEhgDFuAlqnh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 11pt">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,114</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,848</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_zra0uNgTyWM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,395,854</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,247,397</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01I_pp0p" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 22pt">Deferred income tax asset, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3705

1376933 2022954

12950374

10566664

1082661

2677922

15409968

15271245

14114

23848

15395854

15247397

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zXSZpHQn5Vjl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 98%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_zm59GRfwgoH8" style="display: none; text-align: left">Schedule of effective income tax rate reconciliation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. Federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">(1,841,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and local income tax, net of federal income tax effect (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_c20250501__20260430_fKDEp_zAZieO1HOKl2" title="State and local income tax, net of federal income tax effect, percent">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Nontaxable / Nondeductible Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-align: left; padding-bottom: 1pt">Stock Compensation – cancellations/expirations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,623,532</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-18.5</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F03_zB3NfADBBsT6" style="width: 0.25in">(1)</td><td id="xdx_F10_zIVyVTHkvKZ2" style="text-align: justify">The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include California.</td></tr></table> A reconciliation of the provision for income taxes to the amount computed by applying the 21% statutory U.S. federal income tax rate to income before income taxes for years prior to the adoption of ASU 2023-09 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Tax benefit at U.S. Federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-32.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increase (decrease) in tax rate resulting from:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-49.8</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--StockCompensationRate_iP3us-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240501__20250430_z7MNscZ7w8S1" title="Stock-based compensation">-0.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-0.2</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-1841969

0.210

0.000

211325

-0.024

7112

0.001

1623532

-0.185

0.000

0.210

-0.320

0.289

0.115

-0.498

-0.003 -0.001

-0.002

0.000

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAmountsAfCashIncomeTaxesPaidTableTextBlock_zwbrN8zHnWpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - INCOME TAXES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B7_zSwszEVkE9wc" style="display: none; text-align: left">Schedule of amounts of cash income taxes paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30, 2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State and Local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; width: 82%">California</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-align: left">North Carolina</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Foreign</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes, net of amounts refunded</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

800

200

100

1100

15395854

15247397

55300000

23800000

6. STOCK-BASED COMPENSATION 2016 Stock Incentive Plan On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan provides for the issuance of a maximum of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z1rhFbOqXzH9" title="Share-based compensation shares authorized">9,259 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019, the Company’s stockholders approved an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190228__20190301__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z57sTR7hANy6" title="Share-based compensation additional shares authorized">5,556 shares to be available for issuance under the 2016 Plan. Options granted under the 2016 Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20160429__20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zqTKBKThgZgf" title="Share-based compensation expiration period">10 years from the date of grant. Restricted stock awards granted under the 2016 Plan are subject to a vesting period determined at the date of grant. 2021 Stock Incentive Plan In February 2021, the Company’s stockholders approved the Company’s 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan provides for the issuance of a maximum of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20210228__us-gaap--PlanNameAxis__custom--StockIncentivePlan2021Member_pd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">7,407 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. Options granted under the 2021 Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210201__20210228__us-gaap--PlanNameAxis__custom--StockIncentivePlan2021Member_z2K88EYa9RYa" title="Share-based compensation arrangement by share-based payment award, expiration period">10 years from the date of grant. Restricted stock awards granted under the 2021 Plan are subject to a vesting period determined at the date of grant. 2025 Stock Incentive Plan In April 2026, the Company’s stockholders approved, the Company’s 2025 Stock Incentive Plan (the “2025 Plan”). The 2025 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Stock Subject to the 2025 Plan. The maximum number of shares of Common Stock that may be issued under the 2025 Plan is 1,600,000 shares, which number will be increased to the extent that compensation granted under the 2025 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2025 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2025 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2025 Plan. Stock Options. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. A summary of stock option activity for the year ended April 30, 2026, is presented below: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrkBoJt2k2ff" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of share-based payment arrangement, option, activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt; white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt; white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding Options</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares Available for Grant</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (years)</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%">Balance at April 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20250501__20260430_z919tnWwxuPe" title="Shares available for grant begining (in shares)">6,889</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">9,406</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260430_zZuAkFTm3DQ1" title="Weighted average exercise price begining (in dollars per share)">1,802.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260430_zZndbu25Wxv7" title="Weighted average remaining contractual life begining (years)">4.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,590,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250501__20260430_zUmRXECK24Ii" title="Weighted average exercise price, options granted">2.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">- </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,702</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250501__20260430_z7D6pm9rq9Xl" title="Weighted average exercise price, options exercised">1,856.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">16,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,593,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260430_zjolUQg0wle3" title="Weighted average exercise price end (in dollars per share)">6.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250501__20260430_z1VbNGftG6d2" title="Weighted average remaining contractual life end (years)">9.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20260430_z7AujfcfN108" title="Number of shares, options vested and expected to vest at end">1,593,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260430_zlTfPdw2LTK8" title="Weighted average exercise price, options vested and expected to vest at end">6.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250501__20260430_zlrGOrUjPkXj" title="Weighted average remaining contractual life, options vested and expected to vest at end">9.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20260430_zmsAb0359Fbk" title="Aggregate intrinsic value, options vested and expected to vest at end">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">798,704</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430_zdXldswRWwAk" title="Weighted average exercise price, options exercisable at end">10.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250501__20260430_zQxlf9lLJPf7" title="Weighted average remaining contractual life, options exercisable at end">9.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260430_zlKk1VtuUIvb" title="Aggregate intrinsic value, options exercisable at end">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. Stock Options Granted to Employees, Directors and Consultants The estimated fair value of stock options granted to employees, directors and consultants during the year ended April 30, 2026 were calculated using the Black-Scholes option-pricing model using the following assumptions: <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zOnVVpFEVzq9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_z1iD8Dav7k92" style="display: none">Schedule of estimated fair value of stock options granted</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">For the Year Ended April 30, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected term (in years)</td><td style="width: 1%"> </td> <td style="width: 21%; text-align: center">6.25</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: center">93.4%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center">4.4%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: center">0.0%</td></tr> </table> Expected Term: The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company only has a limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant. Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero. There were <span id="xdx_907_ecustom--StockOptionsGrantedToEmployeesAndConsultants_pp0d_do_c20240501__20250430__us-gaap--AwardTypeAxis__custom--EmployeesAndDirectorsMember_zWQYCHQ0BBLf" title="Stock options granted to employees and consultants">no stock options granted during the year ended April 30, 2025. Performance Contingent Stock Options Granted to Employee On November 26, 2019, the Company’s board of directors (the “Board”) granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pd" title="Options granted">3,148 performance and market contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $2,025.00 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target prices for a change in control transaction. The target prices ranged from $13,500 per share to $54,000 per share. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zhQBXbh4IcVh" title="Terms of award">In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $13,500 per share to $27,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of April 30, 2026, the Company’s management believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. On November 29, 2022, the Compensation Committee of the Board granted 1,481 performance-based stock option to the Chief Executive Officer at an exercise price of $1,579.50 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. During the year ended April 30, 2023, the Company believed that it was probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of April 30, 2026, the Company believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized related to Phase I/IIA of ALZN002. Stock-Based Compensation Expense The Company’s results of operations include expenses relating to stock-based compensation for the years ended April 30, 2026 and 2025, were comprised of the following: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zZRS9LGD8W4k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B6_zSWJYZMQmdbk" style="display: none; text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended April 30,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">46,611</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">660,916</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">325,108</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">707,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of April 30, 2026, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0d_c20260430__custom--IncomeStatementsLocationAxis__custom--UnamortizedStockBasedCompensationMember_ziRk7lJ19uhf" title="Unamortized stock-based compensation expense related to unvested employee and non-employee awards">618,000. The weighted-average period over which such stock-based compensation expense will be recognized is approximately <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250501__20260430__custom--IncomeStatementsLocationAxis__custom--StockBasedCompensationMember_zkryEe47Mphc" title="Weighted-average period">2.0 years.

9259

5556

P10Y

7407

P10Y

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrkBoJt2k2ff" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of share-based payment arrangement, option, activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt; white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt; white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding Options</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares Available for Grant</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (years)</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%">Balance at April 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20250501__20260430_z919tnWwxuPe" title="Shares available for grant begining (in shares)">6,889</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">9,406</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260430_zZuAkFTm3DQ1" title="Weighted average exercise price begining (in dollars per share)">1,802.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260430_zZndbu25Wxv7" title="Weighted average remaining contractual life begining (years)">4.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,590,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250501__20260430_zUmRXECK24Ii" title="Weighted average exercise price, options granted">2.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">- </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,702</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250501__20260430_z7D6pm9rq9Xl" title="Weighted average exercise price, options exercised">1,856.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">16,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,593,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260430_zjolUQg0wle3" title="Weighted average exercise price end (in dollars per share)">6.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250501__20260430_z1VbNGftG6d2" title="Weighted average remaining contractual life end (years)">9.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20260430_z7AujfcfN108" title="Number of shares, options vested and expected to vest at end">1,593,406</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260430_zlTfPdw2LTK8" title="Weighted average exercise price, options vested and expected to vest at end">6.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250501__20260430_zlrGOrUjPkXj" title="Weighted average remaining contractual life, options vested and expected to vest at end">9.53</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20260430_zmsAb0359Fbk" title="Aggregate intrinsic value, options vested and expected to vest at end">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">798,704</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260430_zdXldswRWwAk" title="Weighted average exercise price, options exercisable at end">10.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250501__20260430_zQxlf9lLJPf7" title="Weighted average remaining contractual life, options exercisable at end">9.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260430_zlKk1VtuUIvb" title="Aggregate intrinsic value, options exercisable at end">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6889

9406

1802.18

P4Y9M18D

1590000

2.33

P9Y6M14D

5702

1856.49

16889

1593406

6.32

P9Y6M10D

1593406

6.32

P9Y6M10D

798704

10.29

P9Y6M3D

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zOnVVpFEVzq9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_z1iD8Dav7k92" style="display: none">Schedule of estimated fair value of stock options granted</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">For the Year Ended April 30, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected term (in years)</td><td style="width: 1%"> </td> <td style="width: 21%; text-align: center">6.25</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: center">93.4%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center">4.4%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: center">0.0%</td></tr> </table>

P6Y3M

0.934

0.044

0.000

3148

In the event any of the stock price milestones are not achieved within three years

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zZRS9LGD8W4k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B6_zSWJYZMQmdbk" style="display: none; text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended April 30,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">46,611</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">660,916</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">325,108</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">707,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

46611

660916

325108

707527

325108

618000

P2Y

7. WARRANTS Warrant Issuances During 2026 <span id="xdx_908_ecustom--AggregateNumberOfStockRepurchase_do_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__custom--Warrant2026Member_zKICzywmXIC" title="Aggregate number of stock repurchase">No warrants were issued during the year ended April 30, 2026. Warrant Issuances During 2025 During the year ended April 30, 2025, the Company issued warrants to purchase an aggregate of 279,273 shares of Common Stock with a weighted average exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250430__us-gaap--StatementEquityComponentsAxis__custom--Warrant2025Member_pd" title="Exercise price (in dollars per share)">48.96 per share as follows: <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--CommonStockTabeTextBlock_z84HMQpWF7rj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_z7k0lej1OXob" style="display: none; text-align: right">Schedule of Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Issuance</td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Original</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quantity</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiration</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">at Date of Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: right">5/10/2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">8,889</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">112.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5/10/2029 (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">256,591</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">6/25/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">6/25/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">241,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">8/19/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">8/19/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">558,811</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">8/21/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">8/21/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">473,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">9/11/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">9/11/2029(1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66,043</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2/28/2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">2/28/2030</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">577,073</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_zDciIiAYGGD3" style="width: 0.25in">(1)</td><td id="xdx_F1A_zZTNpliEYue1" style="text-align: justify">Cancelled on February 28, 2025</td></tr></table> Based on the terms of the Company’s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the Common Stock, requires settlement in shares and would be classified as equity under ASC 815. The following table summarizes information about Common Stock warrants at April 30, 2026: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zKKkWTCWzZZe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B3_z3C0iS1jJDJ4" style="display: none; text-align: center">Schedule of common stock warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; text-align: center">$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Exercse price (in dollars per share)">8.29</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number Outstanding">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWcmQXTQ72Bd" title="Weighted average remaining contractual life (years)">3.8</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number of warrant exercisable">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Exercse price (in dollars per share)">108.00</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number Outstanding">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zwhKJaFbRc9j" title="Weighted average remaining contractual life (years)">3.3</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number of warrant exercisable">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Exercse price (in dollars per share)">4,050.00</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number Outstanding">1,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zldYkCJnaAQa" title="Weighted average remaining contractual life (years)">0.7</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number of warrant exercisable">1,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Exercse price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Number Outstanding">45</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zmYnCvRtheog" title="Weighted average remaining contractual life (years)">0.1</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Number of warrant exercisable">45</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: center">$8.29 - $8,437.50</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: center">3.7</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrant activity for the year ended April 30, 2026 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfWarrantActivityTableTextBlock_zarPtb6eNDc6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_zDJWRGjAPetf" style="display: none; padding-bottom: 1pt; text-align: left">Schedule of warrant activity</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Number Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Outstanding at April 30, 2025</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">137,051</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNQIc3McHm48" title="Weighted Average Exercise Price, at beginning">103.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Cancelled/Expired</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhBCaJxTL91d" title="Warrant Cancelled/Expired">(1,079</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMO1uVpLC7f5" title="Weighted Average Exercise Price,">4,050.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Outstanding at April 30, 2026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpDK37LMOZMi" title="Weighted Average Exercise Price, at end">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The estimated fair value of warrants granted during the years ended April 30, 2025, were calculated using the Black-Scholes option-pricing model using the following assumptions: <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_z7YDENRbX4U" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - WARRANTS (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B0_z2EpqAPmXIre" style="display: none">Schedule of assumptions used</td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: center">For the year ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">April 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: center">5.00</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td> <td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zdjmgmjPzHad" title="Warrants measurement input">91.0%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Risk-free interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8LOEDzqwwDi" title="Warrants measurement input">4.03%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend yield</td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zv6l0GICoeX2" title="Warrants measurement input">0.0%</td></tr> </table> Expected Term: The expected term represents the contractual life of the warrants granted. Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company only has a limited trading history for its Common Stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant. Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero. 0 279273

48.96

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--CommonStockTabeTextBlock_z84HMQpWF7rj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_z7k0lej1OXob" style="display: none; text-align: right">Schedule of Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Issuance</td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Original</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Date</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quantity</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiration</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">at Date of Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: right">5/10/2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">8,889</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">112.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 19%; text-align: right">5/10/2029 (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">256,591</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">6/25/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">6/25/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">241,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">8/19/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">8/19/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">558,811</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">8/21/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">8/21/2029 (1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">473,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">9/11/2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">9/11/2029(1)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66,043</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2/28/2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">112.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">2/28/2030</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">577,073</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_zDciIiAYGGD3" style="width: 0.25in">(1)</td><td id="xdx_F1A_zZTNpliEYue1" style="text-align: justify">Cancelled on February 28, 2025</td></tr></table> 2024-05-10

8889

112.50

2029-05-10

256591

2024-06-25

13333

112.50

2029-06-25

241340

2024-08-19

17778

112.50

2029-08-19

558811

2024-08-21

22222

112.50

2029-08-21

473512

2024-09-11

8889

112.50

2029-09-11

66043

2025-02-28

111111

112.50

2030-02-28

577073

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zKKkWTCWzZZe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B3_z3C0iS1jJDJ4" style="display: none; text-align: center">Schedule of common stock warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; text-align: center">$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Exercse price (in dollars per share)">8.29</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number Outstanding">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWcmQXTQ72Bd" title="Weighted average remaining contractual life (years)">3.8</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number of warrant exercisable">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Exercse price (in dollars per share)">108.00</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number Outstanding">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zwhKJaFbRc9j" title="Weighted average remaining contractual life (years)">3.3</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number of warrant exercisable">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Exercse price (in dollars per share)">4,050.00</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number Outstanding">1,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zldYkCJnaAQa" title="Weighted average remaining contractual life (years)">0.7</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number of warrant exercisable">1,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Exercse price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Number Outstanding">45</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zmYnCvRtheog" title="Weighted average remaining contractual life (years)">0.1</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightExercisable_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Number of warrant exercisable">45</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260430__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8,437.50</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: center">$8.29 - $8,437.50</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: center">3.7</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8.29

111111

P3Y9M18D

8.29 111111 8.29

108.00

23334

P3Y3M18D

108.00 23334 108.00

4050.00

1482

P0Y8M12D

4050.00 1482 4050.00

8437.50

P0Y1M6D

8437.50 45 8437.50

8.29

8437.50

135972

P3Y8M12D

72.24 135972 72.24 <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfWarrantActivityTableTextBlock_zarPtb6eNDc6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_zDJWRGjAPetf" style="display: none; padding-bottom: 1pt; text-align: left">Schedule of warrant activity</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Number Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Outstanding at April 30, 2025</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">137,051</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNQIc3McHm48" title="Weighted Average Exercise Price, at beginning">103.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Cancelled/Expired</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhBCaJxTL91d" title="Warrant Cancelled/Expired">(1,079</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMO1uVpLC7f5" title="Weighted Average Exercise Price,">4,050.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Outstanding at April 30, 2026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,972</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpDK37LMOZMi" title="Weighted Average Exercise Price, at end">72.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

137051

103.56

-1079

4050.00

135972

72.24

<table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_z7YDENRbX4U" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - WARRANTS (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B0_z2EpqAPmXIre" style="display: none">Schedule of assumptions used</td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: center">For the year ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">April 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: center">5.00</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td> <td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zdjmgmjPzHad" title="Warrants measurement input">91.0%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Risk-free interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8LOEDzqwwDi" title="Warrants measurement input">4.03%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend yield</td> <td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zv6l0GICoeX2" title="Warrants measurement input">0.0%</td></tr> </table> P5Y

0.910

0.0403

0.000

8. COMMITMENTS AND CONTINGENCIES Contractual Obligations On July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the “AL001 Licenses”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer’s, under United States Patent Nos. (i) 9,840,521, entitled “Organic Anion Lithium Ionic Cocrystal Compounds and Compositions”, filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled “Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders”, filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021, the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments to the AL001 Licenses (collectively, the “AL001 License Agreements”). The Third Amendments to the AL001 Licenses modified the timing of the payments for the license fees. The AL001 License Agreements require that the Company pay combined royalty payments of <span id="xdx_906_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pd" title="Percentage of royalty payments on net sales of product">4.5% on net sales of products developed from the licensed technology for AL001. The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 1,650 shares of Common Stock. Minimum royalties for AL001 License Agreements are $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p" title="Payments for royalties">40,000 on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p" title="Payments for royalties">80,000 on the second anniversary of the first commercial sale and $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p" title="Payments for royalties">100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the “ALZN002 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use”, filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31, 2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment to the ALZN002 License (collectively, the “ALZN002 License Agreement”). The Seventh Amendment to the ALZN002 License modified the timing of the payments for the license fees. The ALZN002 License Agreement requires the Company to pay royalty payments of <span id="xdx_90C_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pd" title="Percentage of royalty payments on net sales of product">4% on net sales of products developed from the licensed technology for ALZN002. The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 2,668 shares of Common Stock. Minimum royalties for ALZN002 are $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_zV8pRcL55X51" title="Payments for royalties">20,000 on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_zRTIiH79kYH3" title="Payments for royalties">40,000 on the second anniversary of the first commercial sale and $<span id="xdx_907_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_zExYGW5qOOWj" title="Payments for royalties">50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. On November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the “November AL001 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer’s and (ii) psychiatric diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17, 2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the “November AL001 License Agreements”). The Second Amendments to the November AL001 License modified the timing of the payments for the license fees. The November AL001 License Agreements require the Company to pay royalty payments of <span id="xdx_90B_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pd" title="Percentage of royalty payments on net sales of product">3% on net sales of products developed from the licensed technology for AL001 in those fields. The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_zISiSzw1S8X" title="Payments for royalties">40,000 on the first anniversary of the first commercial sale, $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_zh4orMI2mk51" title="Payments for royalties">80,000 on the second anniversary of the first commercial sale and $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_z8djYqVtrKHe" title="Payments for royalties">100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the Company’s obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company. Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: Original AL001 Licenses: <table cellpadding="0" cellspacing="0" id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zd3GDaRM6vti" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BB_zOZ2uyzTcSR6" style="display: none"> Schedule of contractual obligation, fiscal year maturity</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$50,000*</td> <td style="width: 83%"> <span id="xdx_900_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zZbJtj2JJqbc" title="Due date">Pre-IND Meeting - Completed September 2019</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIFVM1Klm4nl" title="Payment">65,000*</td> <td> <span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z6Ny77BZlnMj" title="Due date">IND application filing - Completed June 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_903_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zMgOLfYbCQK5" title="Payment">190,000*</td> <td> <span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zTx3YHhomVr2" title="Due date">Upon first dosing of patient in a clinical trial - Completed December 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_902_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zPtCR5MvH2Vg" title="Payment">500,000*</td> <td> <span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z6mC3wLe4Nbj" title="Due date">Upon completion of first clinical trial - Completed March 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zVW3cjtRTRh6" title="Payment">1,250,000</td> <td><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zXKEY0M3kij6" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIzRiVRx7hLa" title="Payment">10,000,000</td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIMe9XAwQHFa" title="Due date">Upon FDA NDA approval</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F0C_zN3eT3VEN5b3" style="width: 0.25in">*</td><td id="xdx_F17_zdoubcwcnMw2">Milestone met and completed</td></tr></table> ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$<span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z6TkLz9AGXY9" title="Payment">50,000*</td> <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____z7GUYna7zH15" style="width: 83%">Upon IND application - Completed January 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zAbfWmaPWvob" title="Payment">50,000</td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zjsPJgkPwHyc" title="Due date">Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z9T4WgacOzKi" title="Payment">500,000</td> <td><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zrR4B8nmGeKc" title="Due date">Upon completion of first Phase IIB clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z2Pmy8euwUvh" title="Payment">1,000,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zW5NcouXw3tb" title="Due date">Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zLQIyt3b8LEh" title="Payment">10,000,000</td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zhuiZ2BtAqO8" title="Due date">Upon first commercial sale</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F06_z9J503hIvv3a" style="width: 9pt">*</td><td id="xdx_F14_zOnuFy3o5cq9">Milestone met and completed</td></tr></table> Additional AL001 Licenses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$<span id="xdx_901_eus-gaap--ContractualObligation_pp0d_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zaIqDJXwSdDg" title="Payment">2,000,000</td> <td style="width: 83%"><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zKnnnG0Uytyh" title="Due date">Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90D_eus-gaap--ContractualObligation_pp0d_c20260430__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zKCTIsJunXui" title="Payment">16,000,000</td> <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zualAqH3pRN" title="Due date">First commercial sale</td></tr> </table>

0.045 The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 1,650 shares of Common Stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. 200000

40000

80000

100000

0.04 The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 2,668 shares of Common Stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000 on the second anniversary of the first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. 200000

20000

40000

50000

0.03 The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. 20000

40000

80000

100000

<table cellpadding="0" cellspacing="0" id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zd3GDaRM6vti" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BB_zOZ2uyzTcSR6" style="display: none"> Schedule of contractual obligation, fiscal year maturity</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$50,000*</td> <td style="width: 83%"> <span id="xdx_900_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zZbJtj2JJqbc" title="Due date">Pre-IND Meeting - Completed September 2019</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIFVM1Klm4nl" title="Payment">65,000*</td> <td> <span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z6Ny77BZlnMj" title="Due date">IND application filing - Completed June 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_903_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zMgOLfYbCQK5" title="Payment">190,000*</td> <td> <span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zTx3YHhomVr2" title="Due date">Upon first dosing of patient in a clinical trial - Completed December 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_902_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zPtCR5MvH2Vg" title="Payment">500,000*</td> <td> <span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z6mC3wLe4Nbj" title="Due date">Upon completion of first clinical trial - Completed March 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90F_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zVW3cjtRTRh6" title="Payment">1,250,000</td> <td><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zXKEY0M3kij6" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIzRiVRx7hLa" title="Payment">10,000,000</td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zIMe9XAwQHFa" title="Due date">Upon FDA NDA approval</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F0C_zN3eT3VEN5b3" style="width: 0.25in">*</td><td id="xdx_F17_zdoubcwcnMw2">Milestone met and completed</td></tr></table> ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$<span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z6TkLz9AGXY9" title="Payment">50,000*</td> <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____z7GUYna7zH15" style="width: 83%">Upon IND application - Completed January 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zAbfWmaPWvob" title="Payment">50,000</td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zjsPJgkPwHyc" title="Due date">Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z9T4WgacOzKi" title="Payment">500,000</td> <td><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zrR4B8nmGeKc" title="Due date">Upon completion of first Phase IIB clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z2Pmy8euwUvh" title="Payment">1,000,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zW5NcouXw3tb" title="Due date">Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260430__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zLQIyt3b8LEh" title="Payment">10,000,000</td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zhuiZ2BtAqO8" title="Due date">Upon first commercial sale</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F06_z9J503hIvv3a" style="width: 9pt">*</td><td id="xdx_F14_zOnuFy3o5cq9">Milestone met and completed</td></tr></table> Additional AL001 Licenses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%">$<span id="xdx_901_eus-gaap--ContractualObligation_pp0d_c20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zaIqDJXwSdDg" title="Payment">2,000,000</td> <td style="width: 83%"><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zKnnnG0Uytyh" title="Due date">Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_90D_eus-gaap--ContractualObligation_pp0d_c20260430__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zKCTIsJunXui" title="Payment">16,000,000</td> <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20250501__20260430__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zualAqH3pRN" title="Due date">First commercial sale</td></tr> </table>

50000

Pre-IND Meeting - Completed September 2019

65000

IND application filing - Completed June 2021

190000

Upon first dosing of patient in a clinical trial - Completed December 2021

500000

Upon completion of first clinical trial - Completed March 2022

1250000

Upon first patient treated in a Phase III clinical trial

10000000

Upon FDA NDA approval

50000

Upon IND application - Completed January 2022

50000

Upon first dosing of patient in first Phase I clinical trial

500000

Upon completion of first Phase IIB clinical trial

1000000

Upon first patient treated in a Phase III clinical trial

10000000

Upon first commercial sale

2000000

Upon first patient treated in a Phase III clinical trial

16000000

First commercial sale

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">9.</td><td>EQUITY TRANSACTIONS</td></tr></table> The Company is authorized to issue 10,000,000 shares of Preferred Stock, $0.0001 par value. As of April 30, 2026, the rights, preferences, privileges and restrictions of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. Series B Convertible Preferred Stock On January 31, 2024, the Company and Ault Lending entered into a securities purchase agreement (the “AL SPA”) for the purchase of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to <span id="xdx_907_ecustom--NumberOfSharesPurchase_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_pd" title="Number of shares purchase">66,667 shares of Common Stock. The AL SPA provided that Ault Lending could have purchased up to $6 million of Series B Convertible Preferred Stock in one or more closings. <span id="xdx_905_eus-gaap--TerminationLoansDescription_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zfJbudTGPnse" title="Termination loans description">Ault Lending had the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the “Termination Date”). The final closing did not occur prior to the Termination Date and the AL SPA automatically terminated. During the year ended April 30, 2024, the Company sold 2,100 shares of Series B Convertible Preferred Stock and warrants to purchase <span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p" title="Sale of stock, net proceeds">23,334 shares of Common Stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pd" title="Exercise price (in dollars per share)">108.00, for a total purchase price of $<span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn3n3_dm_c20230501__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaYeVs9UWV1i" title="Sale of stock, number of shares issued">2.1 million. The purchase price was paid by the cancellation of $<span id="xdx_909_ecustom--CancellationsOfCashAdvances_pn3n3_dm_c20230501__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgZvvIqJ4YYi" title="Cancellations of cash advances">1.15 million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024, and $850,000 in cash. The Series B Convertible Preferred Stock has a stated value of $1,000 per share (“Stated Value”) and does not accrue dividends. Each share of Series B Convertible Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Stated Value by $90.00 (the “Conversion Price”). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Company Law and Nasdaq, provided however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to cast, shall not be lower than $78.57 (the “Voting Floor Price”), which represents the closing sale price of the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred Stock receive a liquidation preference ahead of common stockholders. The warrants have an exercise price of $108.00 (the “Exercise Price”) and became exercisable on the first business day after the six-month anniversary of issuance (the “Initial Exercise Date”) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. During the year ended April 30, 2026, Ault Lending converted 2,100 shares of Series B Convertible Preferred Stock into 905,172 shares of Common Stock. On October 14, 2025, the Company filed a Certificate of Elimination to eliminate the Company’s Series B Convertible Preferred Stock. The shares that were designated as Series B Convertible Preferred Stock were returned to the status of authorized but unissued. Series C Preferred Financing On February 28, 2025, the Company and Orchid Finance, LLC (“Orchid”) entered into a Securities and Purchase and Exchange Agreement (the “Orchid SPEA”) for the purchase of up to <span id="xdx_90A_ecustom--NumberOfSharesPurchase_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--OrchidFinanceMember_pd" title="Number of shares purchase">500 shares of Series C Convertible Preferred Stock in several tranche closings and warrants to purchase shares up to <span id="xdx_904_ecustom--NumberOfWarrantsPurchase_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--OrchidFinanceMember_pd" title="Number of warrants purchase">111,111 shares of Common Stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pd" title="Exercise price (in dollars per share)">8.29 (the “Series C Exercise Price”) and are exercisable upon issuance and have a five-year term, expiring on the fifth anniversary of issuance. The Series C Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Series C Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. In addition, <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--OrchidFinanceMember_pd" title="Converted shares">97.7511 shares of Series A Convertible Preferred Stock were exchanged for <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--OrchidFinanceMember_pd" title="Number of shares issued">97.7511 shares of Series C Convertible Preferred Stock. The fair market value of the warrants on the date of issuance was $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20250201__20250228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--OrchidFinanceMember_pp0p" title="Fair market value of warrants">577,073. On April 28, 2025, the Company sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250401__20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zd53b5NBQoI2" title="Sale of stock, number of shares issued">75 shares of Series C Convertible Preferred Stock for a total purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250401__20250428__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pp0p" title="Sale of stock, net proceeds">750,000. On May 29, 2025, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250501__20250529__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7cSl7JOCMAg" title="Sale of stock, number of shares issued">225 shares of Series C Convertible Preferred Stock for a total purchase price of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20250501__20250529__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z50xu7XwmYPd" title="Sale of stock, net proceeds">2.2 million. On June 3, 2025, the Company sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250602__20250603__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztAYZlOkA3Mg" title="Sale of stock, number of shares issued">75 shares of Series C Convertible Preferred Stock for a total purchase price of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250602__20250603__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pp0p" title="Sale of stock, net proceeds">750,000. On June 12, 2025, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250610__20250612__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zCm1hjFowMxj" title="Sale of stock, number of shares issued">105 shares of Series C Convertible Preferred Stock for a total purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20250610__20250612__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zg3BCw2ObE9k" title="Sale of stock, net proceeds">1.0 million. On June 13, 2025, the Company sold <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250611__20250613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zTLI4VEjiY3k" title="Sale of stock, number of shares issued">20 shares of Series C Convertible Preferred Stock for a total purchase price of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250611__20250613__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pp0p" title="Sale of stock, net proceeds">213,000. Effective June 13, 2025, the Orchid SPEA was terminated as all the shares of Series C Convertible Preferred Stock were sold. The Series C Convertible Preferred Stock has a stated value of $10,000 per share (“Series C Stated Value”) and accrued dividends at the rate of 15% per annum, payable quarterly in arrears in cash or paid-in-kind shares, in Orchid’s sole discretion. Each share of Series C Convertible Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Series C Stated Value by (y) the greater of (i) $0.90 per share (“Series C Floor Price”) and (ii) the lesser of (A) $135.00 and (B) 80% of the lowest closing price of our Common Stock during the three trading days immediately prior to the date of conversion into conversion shares (the “Series C Conversion Price”). The Series C Conversion Price was subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Series C Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series C Convertible Preferred Stock were entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series C Convertible Preferred Stock is entitled to cast, shall not be lower than $7.5375 (the “Series C Voting Floor Price”), which represents the closing sale price of the Common Stock on the trading day immediately prior to the date of execution of the Orchid SPEA. The Series C Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. During the year ended April 30, 2025, Orchid converted 23.9712 shares of Series C Convertible Preferred Stock into 44,444 shares of Common Stock. During the year ended April 30, 2026, Orchid converted 575.7176 shares of Series C Convertible Preferred Stock into 2,120,836 shares of Common Stock. On October 14, 2025, the Company filed a Certificate of Elimination to eliminate the Company’s Series C Convertible Preferred Stock. The shares that were designated as Series C Convertible Preferred Stock were returned to the status of authorized but unissued. Common Stock At-the-Market Offerings October 2024 ATM On October 3, 2024, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (“Ascendiant”) as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million (the “2024 Shares”) from time to time, through an “at the market offering” (the “2024 ATM”) as defined in Rule 415 under the Securities Act. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of the 2024 Shares in the 2024 ATM. The offer and sale of the 2024 Shares was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. During the year ended April 30, 2025, the Company sold an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240501__20250430__us-gaap--SubsidiarySaleOfStockAxis__custom--October2024ATMMember_pd" title="Sale of stock, number of shares issued">235,904 shares of Common Stock pursuant to the 2024 ATM for proceeds of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240501__20250430__us-gaap--SubsidiarySaleOfStockAxis__custom--October2024ATMMember_zVhCI8sZCpB" title="Sale of stock, net proceeds">2.7 million. On April 7, 2025, the Company terminated its 2024 ATM. March 2026 ATM On March 6, 2026, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $3.0 million (the “2026 Shares”) from time to time, through an “at the market offering” (the “2026 ATM”) as defined in Rule 415 under the Securities Act. On March 6, 2026, the Company filed a prospectus supplement with the SEC relating to the offer and sale of the 2026 Shares in the 2026 ATM. The offer and sale of the 2026 Shares was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. During the year ended April 30, 2026, the Company sold an aggregate of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250501__20260430__us-gaap--SubsidiarySaleOfStockAxis__custom--March2026ATMMember_pd" title="Sale of stock, number of shares issued">451,298 shares of Common Stock pursuant to the 2026 ATM for proceeds of $795,000.

10000000

0.0001

6000 66667

Ault Lending had the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the “Termination Date”). The final closing did not occur prior to the Termination Date and the AL SPA automatically terminated.

2100

23334

108.00

2100000

1150000

850000

2100

905172

500 111111

8.29

97.7511

577073

750000

225

2200000

750000

105

1000000.0

213000

23.9712

44444

575.7176

2120836

235904

2700000

451298

795000

10. SUBSEQUENT EVENTS From May 1, 2026 to July 22, 2026, the Company sold an aggregate of 535,486 shares of Common Stock pursuant to the 2026 ATM for proceeds of $626,000.

535486

626000

The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include California. Cancelled on February 28, 2025 Milestone met and completed Milestone met and completed